When: Medicare CGM coverage expansion delivers positive surprise

Then: Third confirmation signal

When: Management discloses acquisition target identity, synergy targets, and integration timeline with credible detail

Then: Fourth confirmation signal

HOLD with stop at $105; no new buying until confirmation signals (10 EMA reclaim at $113.15, MACD bullish cross, balance sheet deleveraging)

• Bearish MACD cross below 10 EMA after 30% rally requires consolidation confirmation, not dismissal as a speed bump
• 10 EMA at $113.15 is not anchoring to a round number but a level where momentum reasserts itself; 60 cents of separation matters
• $19.86 billion in new long-term debt locks in fixed costs; Q1 2026 operating income down 20.5% YoY, net income down 18.7% YoY
• 63.2% debt-to-equity post-deal vs ~26% pre-deal nearly triples leverage, materially reducing balance sheet cushion
• $7.4B free cash flow with $4.12B to dividends leaves ~$3.3B discretionary FCF to service incremental debt, fund capex, and absorb integration surprises
• Forward EPS recovery of 96% is consensus assumption; if integration stumbles, 96% becomes 40% and 18.5x forward P/E becomes 25x P/E on reality
• First-of-kind FDA approvals and competitor crisis produced minus 2.2% on broad market up day; stock well below year-ago levels
• Citadel 13F increase does not indicate conviction at $112; position could be 0.1% of their $100B+ book
• Asymmetric setup claimed as $7 downside to $105 vs 7% upside to $120 is actually 1:1 risk-reward with multi-confirmation hurdles required
• 2.26% dividend yield is 200 basis points below 10-year Treasury, not compensating for duration risk or equity opportunity cost

→ vs aggressive: Dismissed MACD cross as a speed bump when it actually signals the stock needs to prove it can hold gains after a strong prior move

→ vs aggressive: Labeled 10 EMA at $113.15 as anchoring bias when it represents a level where momentum must reassert itself before adding capital

→ vs aggressive: Framed $19.86B debt issuance as 'capital deployment at the right moment' when it locks in fixed costs through a depressed earnings period

→ vs aggressive: Claimed catalysts are 'hitting faster than market can price in' when the actual price action shows underperformance despite catalysts

→ vs aggressive: Used Citadel 13F to imply smart-money conviction when it shows no conviction at any particular price level

→ vs aggressive: Called 6.2% downside 'defined' when in reality it's capital that must be recovered before any upside is realized

→ vs aggressive: Dismisses yield gap as a 'bond trader framework' when it is actually a relative value framework applicable to all income-producing instruments

HOLD with modified confirmation requirements (any 2 of 3 signals) and tiered position sizing: 1-2% starter at current levels with tighter stop around 108-109, scaling to 2-3% on first confirming signal and 5% on sustained move above 120.

• Catalyst stack is genuinely impressive: FDA De Novo clearance, CE Mark for LAA closure device, NEC settlement at 670 million, and Ken Griffin's 13F accumulation are all valid signal points
• Entry at 112.47 with stop at 105 offers ~6.7% risk versus ~6.7% upside to 120 target - this is not true asymmetry, it's a coin flip
• Q1 2026 results are not noise: operating income down 20.5% YoY and net income down 18.7% YoY reflect the 19.86 billion in new debt burden
• Forward EPS recovery to 6.06 dollars requires near-doubling of earnings - this is consensus assumption, not fact
• Net debt of 27.2 billion against 7.4 billion in free cash flow with deleveraging plan is manageable for this cash flow profile
• Requiring all three signals (10 EMA reclaim, positive MACD histogram, Q2 earnings recovery) before acting is too conservative given the dense catalyst calendar
• Stop at 105 could be tightened to 107-108 given 200 SMA at 105.65
• The price action printing minus 2.2% on broad up day reflects market waiting for execution evidence, not necessarily informed bearishness

→ vs aggressive: Treats Q1 2026 operating income down 20.5% YoY and net income down 18.7% YoY as footnotes rather than evidence of full interest expense burden from 19.86 billion in new debt plus integration costs

→ vs aggressive: Frames the entry at 112.47, stop at 105, target at 120 as asymmetric when the math shows equal 6.7% risk and reward - not high conviction, a coin flip

→ vs conservative: Confirmation stacking requiring all three signals is too conservative; by the time all align, the stock will have moved meaningfully higher, leaving money on the table

→ vs conservative: Overweights yield gap argument (2.26% sitting 200 basis points below 10-year) for a stock whose thesis is quality compounder status with dividend growth, not yield capture

→ vs conservative: Overinterprets minus 2.2% on broad up day as informed capital knowing something - the parsimonious explanation is market waiting for execution evidence, not bearishness

→ vs conservative: Implicitly frames 27.2 billion net debt as fatal risk when 7.4 billion in free cash flow and deleveraging plan make it manageable